52-week Open Label Safety-Tolerability Study

A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia who are experiencing inadequate response or who are having issues with side effects, general tolerability, or overall effectiveness of their current antipsychotic medication and desire to change medications, or who have completed their participation in current LB-102 clinical studies

Inclusion Criteria:

• Provide ICF
• Patients clinically stable PANSS </= 70 at screening
• CGI-S </+ 3 at screening
• Medically stable
• BMI 18 -40
• Taking oral antipsychotic treatment for at least 30 days
• Have stable living environment

Exclusion Criteria:

• Sexually active M/F patients not willing to use highly effective contraception
• Breast feeding
• History of treatment resistance to schizophrenia medications
• DSM-5 current diagnosis other than schizophrenia
• Risk of suicidal behavior
• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other